Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis

Inflammatory Bowel Diseases

Volumn 18, Issue 5, 2012, Pages 803-808

  Ogata, Haruhiko ^a   Kato, Jun ^b   Hirai, Fumihito ^c   Hida, Nobuyuki ^d   Matsui, Toshiyuki ^c   Matsumoto, Takayuki ^d   Koyanagi, Katsuyoshi ^e   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c Fukuoka University Chikushi Hospital   (Japan)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

^e ASTELLAS PHARMA INC   (Japan)

Author keywords

Immunosuppressive therapy; Tacrolimus; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CHOLESTEROL; CREATININE; ELECTROLYTE; GLUCOSE; PLACEBO; PREDNISOLONE; STEROID; TACROLIMUS;

ARTICLE; BACKACHE; BLOOD PRESSURE; BODY TEMPERATURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY INDEX; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; ELECTROLYTE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEADACHE; HOSPITAL PATIENT; HOT FLUSH; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; OPPORTUNISTIC INFECTION; PARESTHESIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; STEROID THERAPY; TREATMENT RESPONSE; TREMOR; ULCER HEALING; ULCERATIVE COLITIS; UPPER ABDOMINAL PAIN; UREA NITROGEN BLOOD LEVEL; VITAL SIGN;

ADMINISTRATION, ORAL; COLITIS, ULCERATIVE; DISEASE MANAGEMENT; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PATIENT COMPLIANCE; REMISSION INDUCTION; STEROIDS; TACROLIMUS; TREATMENT OUTCOME;

EID: 84859801314     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21853     Document Type: Article

References (14)

1. Fellermann K, Ludwig D, Stahl M, et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol. 1998;93:1860-1866. (Pubitemid 29071695)
2. Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis. 2002;8:317-324.
3. Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17:1273-1281. (Pubitemid 36693728)
4. Högenauer C, Wenzl HH, Hinterleitner TA, et al. Effect of oral tacrolimus (FK506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther. 2003;18:415-423. (Pubitemid 37070240)
5. Ogata H, Matsui T, Nakamura M, et al. A randomized dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006;55:1255-1262. (Pubitemid 44277355)
6. Marion JF, Rubin PH, Present DH. Differential diagnosis of chronic ulcerative colitis and Crohn's disease. In: Kirsner JB, ed. Inflammatory Bowel Disease, 5th ed. Philadelphia: W.B. Saunders; 2000:315-325.
7. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis, a randomized study. N Engl J Med. 1987;317:1625-1629. (Pubitemid 18010466)
8. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353:2462-2476. (Pubitemid 41770166)
9. Kobayashi T, Naganuma M, Okamoto S, et al. Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis. J Gastroenterol. 2010;45:1129-1137.
10. Naganuma M, Ichikawa H, Inoue N, et al. Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients. J Gastroenterol. 2010;45:936-943.
11. Baumgart DC, Pintoffl JP, Sturm A, et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease - a long-term follow-up. Am J Gastroenterol. 2006;101:1048-1056. (Pubitemid 43725319)
12. Yamamoto S, Nakase H, Mikami S, et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther. 2008;28:589-597.
13. Yamamoto S, Nakase H, Matsuura M, et al. Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis. J Clin Gastroenterol. 2011;45:526-530.
14. Naganuma M, Fujii T, Watanabe M, et al. The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol. 2011;46:129-137.